Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 28,100 shares, an increase of 5.2% from the November 15th total of 26,700 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Analyst Ratings Changes

Separately, HC Wainwright upgraded Basilea Pharmaceutica to a “strong-buy” rating in a research note on Monday, September 23rd.

Basilea Pharmaceutica Stock Performance

BPMUF stock opened at $52.83 on Wednesday. The firm has a 50 day moving average of $52.74 and a 200-day moving average of $50.37. Basilea Pharmaceutica has a 12 month low of $38.60 and a 12 month high of $52.83.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.